drugset
drugset / Trial / NCT05911841

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT05911841 ↗

Phase 2 Terminated 234 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Timeline

Start
2023-06-21
Primary completion
2024-10-10
Completion
2025-03-14

Outcome

Outcome not reported

Stopped: “The decision to terminate the study was due to efficacy/effectiveness reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject UCENPRUBART Monoclonal antibody 150 mg Subcutaneous
Subject UCENPRUBART Monoclonal antibody 300 mg Subcutaneous
Subject UCENPRUBART Monoclonal antibody 800 mg Subcutaneous

Indications

atopic eczema